Breaking News

Yesterday
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
Options
Gilead call volume above normal and directionally bullish » 13:45
06/04/20
06/04
13:45
06/04/20
13:45
GILD

Gilead

$76.21 /

+1.84 (+2.47%)

Bullish option flow…

Bullish option flow detected in Gilead with 42,514 calls trading, 1.1x expected, and implied vol increasing over 3 points to 35.59%. Aug-20 87.5 calls and Jun-20 75 calls are the most active options, with total volume in those strikes near 8,700 contracts. The Put/Call Ratio is 0.16. Earnings are expected on July 30th.

ShowHide Related Items >><<
GILD Gilead
$76.21 /

+1.84 (+2.47%)

GILD Gilead
$76.21 /

+1.84 (+2.47%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/03/20 SVB Leerink
Gilead upgraded to Outperform from Market Perform at SVB Leerink
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
GILD Gilead
$76.21 /

+1.84 (+2.47%)

GILD Gilead
$76.21 /

+1.84 (+2.47%)

GILD Gilead
$76.21 /

+1.84 (+2.47%)

GILD Gilead
$76.21 /

+1.84 (+2.47%)

Conference/Events
SVB Leerink biotech analyst to hold analyst/industry conference call » 10:11
06/04/20
06/04
10:11
06/04/20
10:11
RCUS

Arcus Biosciences

$31.00 /

-0.13 (-0.42%)

, GILD

Gilead

$74.90 /

+0.53 (+0.71%)

Biotech Analyst Porges…

Biotech Analyst Porges discusses Gilead (GILD) rating increase to Outperform from Market Perform due to Remdesivir sales and the recently announced collaboratoin with Arcus (RCUS) on an Analyst/Industry conference call to be held on June 4 at 11 am.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$31.00 /

-0.13 (-0.42%)

GILD Gilead
$74.90 /

+0.53 (+0.71%)

RCUS Arcus Biosciences
$31.00 /

-0.13 (-0.42%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
GILD Gilead
$74.90 /

+0.53 (+0.71%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform from Market Perform at SVB Leerink
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
RCUS Arcus Biosciences
$31.00 /

-0.13 (-0.42%)

GILD Gilead
$74.90 /

+0.53 (+0.71%)

RCUS Arcus Biosciences
$31.00 /

-0.13 (-0.42%)

GILD Gilead
$74.90 /

+0.53 (+0.71%)

RCUS Arcus Biosciences
$31.00 /

-0.13 (-0.42%)

GILD Gilead
$74.90 /

+0.53 (+0.71%)

RCUS Arcus Biosciences
$31.00 /

-0.13 (-0.42%)

GILD Gilead
$74.90 /

+0.53 (+0.71%)

Hot Stocks
Gilead, Galapagos announce Week 52 results from Phase 3 FINCH 1, FINCH 3 studies » 06:19
06/04/20
06/04
06:19
06/04/20
06:19
GILD

Gilead

$74.37 /

+1.12 (+1.53%)

, GLPG

Galapagos

$200.06 /

+2.16 (+1.09%)

Gilead Sciences (GILD)…

Gilead Sciences (GILD) and Galapagos NV (GLPG) announced Week 52 results from the Phase 3 FINCH 1 and FINCH 3 studies of filgotinib, an investigational, oral, selective JAK1 inhibitor, in adults with moderately to severely active rheumatoid arthritis, or RA. The data demonstrate sustained efficacy and a consistent safety profile with up to 52 weeks of filgotinib treatment across RA patient populations. The new data are among 15 abstracts on filgotinib in RA that will be presented at the European League Against Rheumatism, EULAR, European E-Congress of Rheumatology 2020. "Many people with RA struggle with uncontrolled symptoms that affect their daily lives. We are working to develop effective and well-tolerated treatment options that will make a difference in the lives of patients," said Mark Genovese, MD, Senior Vice President, Inflammation, Gilead Sciences. "These data add to the body of evidence supporting filgotinib as a potential treatment option for a range of RA patients."

ShowHide Related Items >><<
GLPG Galapagos
$200.06 /

+2.16 (+1.09%)

GILD Gilead
$74.37 /

+1.12 (+1.53%)

GILD Gilead
$74.37 /

+1.12 (+1.53%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/03/20 SVB Leerink
Gilead upgraded to Outperform from Market Perform at SVB Leerink
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
GLPG Galapagos
$200.06 /

+2.16 (+1.09%)

05/21/20 Piper Sandler
Gilead's filgotinib likely being underestimated by Street, says Piper Sandler
05/21/20 H.C. Wainwright
Galapagos price target lowered to $270 from $302 at H.C. Wainwright
05/18/20 UBS
Galapagos price target raised to EUR 200 from EUR 194 at UBS
05/15/20 Barclays
Galapagos price target raised to EUR 235 from EUR 225 at Barclays
GLPG Galapagos
$200.06 /

+2.16 (+1.09%)

GILD Gilead
$74.37 /

+1.12 (+1.53%)

GILD Gilead
$74.37 /

+1.12 (+1.53%)

GLPG Galapagos
$200.06 /

+2.16 (+1.09%)

GILD Gilead
$74.37 /

+1.12 (+1.53%)

GILD Gilead
$74.37 /

+1.12 (+1.53%)

Wednesday
On The Fly
Gilead, Zoom Video upgrades among today's top calls on Wall Street » 10:05
06/03/20
06/03
10:05
06/03/20
10:05
GILD

Gilead

$73.54 /

+0.29 (+0.40%)

, RCUS

Arcus Biosciences

$34.28 /

-0.19 (-0.55%)

, ZM

Zoom Video

$210.75 /

+2.75 (+1.32%)

, COUP

Coupa Software

$223.00 /

-6.77 (-2.95%)

, OKTA

Okta

$197.99 /

-1.47 (-0.74%)

, SHOP

Shopify

$769.96 /

-9.02 (-1.16%)

, DDOG

Datadog

$70.26 /

-0.57 (-0.80%)

, NIO

NIO Inc.

$5.19 /

+0.505 (+10.79%)

, MAT

Mattel

$10.18 /

+0.54 (+5.60%)

, RCL

Royal Caribbean

$56.32 /

+0.36 (+0.64%)

, CCL

Carnival

$17.17 /

+0.3 (+1.78%)

, NCLH

Norwegian Cruise Line

$17.37 /

-0.015 (-0.09%)

Check out today's top…

Open Full Text

ShowHide Related Items >><<
ZM Zoom Video
$210.75 /

+2.75 (+1.32%)

SHOP Shopify
$769.96 /

-9.02 (-1.16%)

RCUS Arcus Biosciences
$34.28 /

-0.19 (-0.55%)

RCL Royal Caribbean
$56.32 /

+0.36 (+0.64%)

OKTA Okta
$197.99 /

-1.47 (-0.74%)

NIO NIO Inc.
$5.19 /

+0.505 (+10.79%)

NCLH Norwegian Cruise Line
$17.37 /

-0.015 (-0.09%)

MAT Mattel
$10.18 /

+0.54 (+5.60%)

GILD Gilead
$73.54 /

+0.29 (+0.40%)

DDOG Datadog
$70.26 /

-0.57 (-0.80%)

COUP Coupa Software
$223.00 /

-6.77 (-2.95%)

CCL Carnival
$17.17 /

+0.3 (+1.78%)

GILD Gilead
$73.54 /

+0.29 (+0.40%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal
06/03/20 SVB Leerink
Gilead upgraded to Outperform from Market Perform at SVB Leerink
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
RCUS Arcus Biosciences
$34.28 /

-0.19 (-0.55%)

05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
ZM Zoom Video
$210.75 /

+2.75 (+1.32%)

06/03/20 Needham
Zoom Video price target raised to $230 from $140 at Needham
06/03/20 FBN Securities
Zoom Video upgraded to Outperform from Sector Perform at FBN Securities
06/03/20 JPMorgan
Wowed JPMorgan raises Zoom Video price target to $220 from $150
06/03/20 Baird
Zoom Video price target raised to $230 from $180 at Baird
COUP Coupa Software
$223.00 /

-6.77 (-2.95%)

06/03/20
Zoom Video upgraded to Buy at DA Davidson on 'huge acceleration in growth'
06/02/20 Wells Fargo
Coupa Software price target raised to $200 from $120 at Wells Fargo
05/28/20 Wedbush
Coupa Software downgraded to Neutral at Wedbush
05/28/20 Wedbush
Coupa Software downgraded to Neutral from Outperform at Wedbush
OKTA Okta
$197.99 /

-1.47 (-0.74%)

06/01/20 Guggenheim
Okta price target raised to $200 from $145 at Guggenheim
05/29/20 DA Davidson
Okta price target raised to $210 from $140 at DA Davidson
05/29/20 JPMorgan
Okta price target raised to $192 from $154 at JPMorgan
SHOP Shopify
$769.96 /

-9.02 (-1.16%)

05/21/20 Roth Capital
Roth boosts Shopify target to $750, says valuation remains 'stretched'
05/21/20 Canaccord
Shopify price target raised to $700 from $650 at Canaccord
05/20/20 Baird
Shopify still in early stages of creating 'cutting-edge' platform, says Baird
DDOG Datadog
$70.26 /

-0.57 (-0.80%)

05/13/20 Barclays
Dynatrace price target raised to $38 from $28 at Barclays
05/12/20 JPMorgan
Datadog price target raised to $65 from $60 at JPMorgan
05/12/20 Needham
Datadog price target raised to $70 from $58 at Needham
NIO NIO Inc.
$5.19 /

+0.505 (+10.79%)

06/02/20 Goldman Sachs
NIO Inc. upgraded to Buy from Neutral at Goldman Sachs
05/27/20
Fly Intel: Top five analyst upgrades
05/27/20 JPMorgan
NIO Inc. upgraded to Neutral from Underweight at JPMorgan
05/06/20 BofA
NIO Inc. upgraded to Buy from Neutral at BofA
MAT Mattel
$10.18 /

+0.54 (+5.60%)

06/03/20 Jefferies
Jefferies upgrades Mattel to Buy with $13 price target
06/03/20 Jefferies
Mattel upgraded to Buy from Hold at Jefferies
05/01/20 JPMorgan
JPMorgan lowers Mattel target to $11, removed from Analyst Focus List
04/21/20 Goldman Sachs
Mattel price target lowered to $10 from $14 at Goldman Sachs
RCL Royal Caribbean
$56.32 /

+0.36 (+0.64%)

06/03/20 Morgan Stanley
Royal Caribbean reinstated at Underweight from Equal Weight at Morgan Stanley
05/28/20 Stifel
Royal Caribbean price target raised to $62 from $52 at Stifel
05/21/20
Fly Intel: Top five analyst initiations
05/21/20 JPMorgan
Royal Caribbean price target lowered to $50 from $55 at JPMorgan
CCL Carnival
$17.17 /

+0.3 (+1.78%)

06/03/20 Morgan Stanley
Carnival reinstated with an Underweight from Equal Weight at Morgan Stanley
05/21/20 Credit Suisse
Cruise stocks initiated at Credit Suisse, sees unique vacation opportunity
05/21/20 Credit Suisse
Carnival initiated with a Neutral at Credit Suisse
NCLH Norwegian Cruise Line
$17.37 /

-0.015 (-0.09%)

06/03/20 Morgan Stanley
Norwegian Cruise downgraded to Underweight from Equal Weight at Morgan Stanley
05/21/20 Credit Suisse
Norwegian Cruise Line initiated with an Outperform at Credit Suisse
ZM Zoom Video
$210.75 /

+2.75 (+1.32%)

SHOP Shopify
$769.96 /

-9.02 (-1.16%)

RCUS Arcus Biosciences
$34.28 /

-0.19 (-0.55%)

RCL Royal Caribbean
$56.32 /

+0.36 (+0.64%)

OKTA Okta
$197.99 /

-1.47 (-0.74%)

NIO NIO Inc.
$5.19 /

+0.505 (+10.79%)

NCLH Norwegian Cruise Line
$17.37 /

-0.015 (-0.09%)

MAT Mattel
$10.18 /

+0.54 (+5.60%)

GILD Gilead
$73.54 /

+0.29 (+0.40%)

DDOG Datadog
$70.26 /

-0.57 (-0.80%)

COUP Coupa Software
$223.00 /

-6.77 (-2.95%)

CCL Carnival
$17.17 /

+0.3 (+1.78%)

ZM Zoom Video
$210.75 /

+2.75 (+1.32%)

SHOP Shopify
$769.96 /

-9.02 (-1.16%)

RCUS Arcus Biosciences
$34.28 /

-0.19 (-0.55%)

RCL Royal Caribbean
$56.32 /

+0.36 (+0.64%)

OKTA Okta
$197.99 /

-1.47 (-0.74%)

NIO NIO Inc.
$5.19 /

+0.505 (+10.79%)

NCLH Norwegian Cruise Line
$17.37 /

-0.015 (-0.09%)

MAT Mattel
$10.18 /

+0.54 (+5.60%)

GILD Gilead
$73.54 /

+0.29 (+0.40%)

DDOG Datadog
$70.26 /

-0.57 (-0.80%)

CCL Carnival
$17.17 /

+0.3 (+1.78%)

ZM Zoom Video
$210.75 /

+2.75 (+1.32%)

SHOP Shopify
$769.96 /

-9.02 (-1.16%)

RCUS Arcus Biosciences
$34.28 /

-0.19 (-0.55%)

RCL Royal Caribbean
$56.32 /

+0.36 (+0.64%)

OKTA Okta
$197.99 /

-1.47 (-0.74%)

NIO NIO Inc.
$5.19 /

+0.505 (+10.79%)

NCLH Norwegian Cruise Line
$17.37 /

-0.015 (-0.09%)

MAT Mattel
$10.18 /

+0.54 (+5.60%)

GILD Gilead
$73.54 /

+0.29 (+0.40%)

DDOG Datadog
$70.26 /

-0.57 (-0.80%)

COUP Coupa Software
$223.00 /

-6.77 (-2.95%)

CCL Carnival
$17.17 /

+0.3 (+1.78%)

ZM Zoom Video
$210.75 /

+2.75 (+1.32%)

SHOP Shopify
$769.96 /

-9.02 (-1.16%)

RCUS Arcus Biosciences
$34.28 /

-0.19 (-0.55%)

RCL Royal Caribbean
$56.32 /

+0.36 (+0.64%)

OKTA Okta
$197.99 /

-1.47 (-0.74%)

NIO NIO Inc.
$5.19 /

+0.505 (+10.79%)

NCLH Norwegian Cruise Line
$17.37 /

-0.015 (-0.09%)

MAT Mattel
$10.18 /

+0.54 (+5.60%)

GILD Gilead
$73.54 /

+0.29 (+0.40%)

DDOG Datadog
$70.26 /

-0.57 (-0.80%)

COUP Coupa Software
$223.00 /

-6.77 (-2.95%)

CCL Carnival
$17.17 /

+0.3 (+1.78%)

Upgrade
Gilead upgraded to Outperform at SVB Leerink on remdesivir sales, Arcus deal » 08:15
06/03/20
06/03
08:15
06/03/20
08:15
GILD

Gilead

$73.25 /

-1.9 (-2.53%)

, RCUS

Arcus Biosciences

$34.47 /

+1.37 (+4.14%)

As previously reported,…

As previously reported, SVB Leerink analyst Geoffrey Porges upgraded Gilead (GILD) to Outperform from Market Perform with a price target of $94, up from $85. His upgrade is based on the inclusion of his first revenue and profit contribution for remdesivir, and also incorporation of the product opportunities from the recently announced Arcus (RCUS) collaboration. The analyst forecasts remdesivir sales reaching an annual revenue peak of $7.7B in 2022. While Porges is initially forecasting sales of less $1B for the Arcus products, he believes this deal finally provides Gilead critical mass in oncology with a diverse and synergistic pipeline, and boosts his confidence for investing in the stock long-term.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$34.47 /

+1.37 (+4.14%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

06/03/20 SVB Leerink
Gilead upgraded to Outperform from Market Perform at SVB Leerink
06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
RCUS Arcus Biosciences
$34.47 /

+1.37 (+4.14%)

05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
RCUS Arcus Biosciences
$34.47 /

+1.37 (+4.14%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

RCUS Arcus Biosciences
$34.47 /

+1.37 (+4.14%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

RCUS Arcus Biosciences
$34.47 /

+1.37 (+4.14%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

RCUS Arcus Biosciences
$34.47 /

+1.37 (+4.14%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

Upgrade
Gilead upgraded to Outperform from Market Perform at SVB Leerink » 07:31
06/03/20
06/03
07:31
06/03/20
07:31
GILD

Gilead

$73.25 /

-1.9 (-2.53%)

SVB Leerink analyst…

SVB Leerink analyst Geoffrey Porges upgraded Gilead to Outperform from Market Perform with a $94 price target.

ShowHide Related Items >><<
GILD Gilead
$73.25 /

-1.9 (-2.53%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

06/02/20 Citi
Arcus Biosciences price target raised to $41 from $15 at Citi
06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
GILD Gilead
$73.25 /

-1.9 (-2.53%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

GILD Gilead
$73.25 /

-1.9 (-2.53%)

Tuesday
Recommendations
Arcus Biosciences price target raised to $41 from $15 at Citi » 06:37
06/02/20
06/02
06:37
06/02/20
06:37
RCUS

Arcus Biosciences

$33.10 /

+1.63 (+5.18%)

, GILD

Gilead

$75.15 /

-2.64 (-3.39%)

Citi analyst Yigal…

Citi analyst Yigal Nochomovitz raised the firm's price target on Arcus Biosciences (RCUS) to $41 from $15 and keeps a Buy rating on the shares. The collaboration with Gilead (GILD) adds "meaningful validation" to Arcus's immune oncology pipeline, Nochomovitz tells investors in a research note. The analyst believes Gilead's licensure of Arcus's PD-1 inhibitor zimberelimab and opt-in interest in AB154 and AB928 "demonstrates substantial confidence" in Arcus's pipeline.

ShowHide Related Items >><<
RCUS Arcus Biosciences
$33.10 /

+1.63 (+5.18%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

RCUS Arcus Biosciences
$33.10 /

+1.63 (+5.18%)

05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
05/14/20 Mizuho
Arcus Biosciences price target raised to $40 from $22 at Mizuho
GILD Gilead
$75.15 /

-2.64 (-3.39%)

06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
RCUS Arcus Biosciences
$33.10 /

+1.63 (+5.18%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

RCUS Arcus Biosciences
$33.10 /

+1.63 (+5.18%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

RCUS Arcus Biosciences
$33.10 /

+1.63 (+5.18%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

RCUS Arcus Biosciences
$33.10 /

+1.63 (+5.18%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

Periodicals
Emergency use of Gilead's remdesivir approved in India, Reuters reports » 06:22
06/02/20
06/02
06:22
06/02/20
06:22
GILD

Gilead

$75.15 /

-2.64 (-3.39%)

India's government…

India's government has approved Gilead Sciences's antiviral drug remdesivir for emergency use in treating COVID-19 patients, Reuters' Anuron Kumar Mitra and Manas Mishra report. "[Remdesivir] approved on June 1 under emergency use with condition for five dose administration," the Drugs Controller General of India said in an email statement. Reference Link

ShowHide Related Items >><<
GILD Gilead
$75.15 /

-2.64 (-3.39%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
GILD Gilead
$75.15 /

-2.64 (-3.39%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

Monday
Hot Stocks
Ligand working with Gilead to meet need for remdesivir » 16:58
06/01/20
06/01
16:58
06/01/20
16:58
LGND

Ligand

$102.28 /

+0.55 (+0.54%)

, GILD

Gilead

$75.15 /

-2.64 (-3.39%)

Ligand Pharmaceuticals…

Ligand Pharmaceuticals Incorporated (LGND) announces that Chief Executive Officer John Higgins issued a letter to Ligand's Captisol customers. "Ligand is in a period of momentous planning and scale-up. As you may know, Captisol is a key ingredient in Gilead Sciences' (GILD) antiviral remdesivir, which is being developed as a treatment for COVID-19. This drug has received an unprecedented amount of attention," Higgins said. "I want to update you as to where Ligand stands in fulfilling our commitment to all our Captisol customers and discuss our plans to increase manufacturing capacity. On behalf of the entire team at Ligand, I want you to know we are dedicated to fulfilling your Captisol needs with the highest level of service, reliability and quality." "In January 2020 Gilead informed us they needed Captisol for remdesivir as a potential treatment for COVID-19. That outreach was a natural development as we have had a relationship with Gilead for several years beginning when this drug was being tested for Ebola," Higgins added. "We were witnessing the novel coronavirus emerge as a real threat to public health, and as it became clear the virus was not going to be contained and the global health crisis became a pandemic, we anticipated Captisol demand was going to increase substantially. We immediately began coordination on the necessary planning for production needs as initial orders for Captisol were received and steadily grew. Clinical work with remdesivir in COVID-19 has been promising as studies indicate the drug reduces the length of hospital stay and may lower the mortality rate in patients with severe disease. On May 1 remdesivir received an Emergency Use Authorization from the U.S. Food and Drug Administration and became the first new drug authorized as a treatment for COVID-19. The medical need was obvious, immense and growing. Then on June 1, Gilead announced additional data in patients with moderate disease showing again that remdesivir has the potential to meaningfully benefit patients. We are working closely with Gilead to meet the urgent need for supply of this medicine. In light of Gilead's public statements, we expect their Captisol requirements will increase significantly over the next couple of years, and we expect orders beyond that. To meet global demand quickly, Gilead is establishing a consortium of generic pharmaceutical companies around the world to manufacture remdesivir. We have established initial agreements with four of those companies and are prepared to fill the full production and supply needs for all companies producing remdesivir."

ShowHide Related Items >><<
LGND Ligand
$102.28 /

+0.55 (+0.54%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

LGND Ligand
$102.28 /

+0.55 (+0.54%)

04/29/20 Craig-Hallum
Ligand has 'significant upside' if remdesivir is approved, says Craig-Hallum
04/08/20 H.C. Wainwright
Ligand price target lowered to $229 from $237 at H.C. Wainwright
04/06/20 H.C. Wainwright
H.C. Wainwright says Captisol a 'key focus' for Ligand, reiterates Buy
03/24/20 Argus
Ligand downgraded to Hold from Buy at Argus
GILD Gilead
$75.15 /

-2.64 (-3.39%)

06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
LGND Ligand
$102.28 /

+0.55 (+0.54%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

LGND Ligand
$102.28 /

+0.55 (+0.54%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

Conference/Events
Cantor Fitzgerald biopharma analysts to hold analyst/industry conference call » 16:36
06/01/20
06/01
16:36
06/01/20
16:36
CBAY

CymaBay

$3.80 /

+0.09 (+2.43%)

, ICPT

Intercept

$73.54 /

+1.14 (+1.57%)

, GILD

Gilead

$75.15 /

-2.64 (-3.39%)

, NVO

Novo Nordisk

$65.73 /

-0.215 (-0.33%)

, LLY

Eli Lilly

$152.30 /

-0.84 (-0.55%)

Specialty Pharma Analysts…

Specialty Pharma Analysts Chen & Kim and Biopharma Analyst Folkes discuss the unment needs in the treatment of Type 2 Diabetes, NASH and Obesity, Novo's Rybelsus usage, Eli Lilly's Trulicity and Tirzepatide and a review of NASH treatments in development from Gilead, Novo, Intercept and CymaBay on an Analyst/Industry conference call to be held on June 5 at 11 am.

ShowHide Related Items >><<
NVO Novo Nordisk
$65.73 /

-0.215 (-0.33%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ICPT Intercept
$73.54 /

+1.14 (+1.57%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

CBAY CymaBay
$3.80 /

+0.09 (+2.43%)

CBAY CymaBay
$3.80 /

+0.09 (+2.43%)

05/26/20 H.C. Wainwright
CymaBay upgraded to Buy from Neutral at H.C. Wainwright
05/15/20 Citi
CymaBay price target raised to $7 from $1.60 at Citi
05/12/20 B. Riley FBR
CymaBay upgraded to Buy from Neutral at B. Riley FBR
05/12/20
Fly Intel: Top five analyst upgrades
ICPT Intercept
$73.54 /

+1.14 (+1.57%)

05/22/20 B. Riley FBR
Intercept weakness on 'slight' delay should be bought, says B. Riley FBR
05/22/20 Raymond James
Intercept downgraded at Raymond James after OCA NDA is postponed
05/22/20 Raymond James
Intercept downgraded to Outperform from Strong Buy at Raymond James
05/22/20 Stifel
Intercept uncertainty, lack of clarity in NASH to hurt sentiment, says Stifel
GILD Gilead
$75.15 /

-2.64 (-3.39%)

06/01/20 Piper Sandler
Remdesivir now proven effective for COVID-19 in three studies, says Piper
05/27/20 Raymond James
Raymond James keeps Market Perform on Gilead following Arcus partnership
05/27/20 Wedbush
Arcus Biosciences price target raised to $48 from $40 at Wedbush
05/27/20 Piper Sandler
Piper says partnership more favorable for Gilead than outright Arcus purchase
NVO Novo Nordisk
$65.73 /

-0.215 (-0.33%)

05/18/20 Morgan Stanley
Novo Nordisk price target raised to DKK 435 from DKK 425 at Morgan Stanley
05/13/20 JPMorgan
Novo Nordisk price target raised to DKK 480 from DKK 460 at JPMorgan
05/11/20
Fly Intel: Top five analyst downgrades
05/11/20 UBS
Novo Nordisk downgraded to Neutral from Buy at UBS
LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

06/01/20 Morgan Stanley
Lilly trial has higher risk and reward after Pfizer failure, says Morgan Stanley
05/29/20 Raymond James
Blueprint approval for pralsetinib could come before PDUFA, says Raymond James
04/24/20 Cantor Fitzgerald
Eli Lilly price target raised to $185 from $156 at Cantor Fitzgerald
04/24/20 Mizuho
Eli Lilly price target raised to $155 from $148 at Mizuho
NVO Novo Nordisk
$65.73 /

-0.215 (-0.33%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ICPT Intercept
$73.54 /

+1.14 (+1.57%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

CBAY CymaBay
$3.80 /

+0.09 (+2.43%)

NVO Novo Nordisk
$65.73 /

-0.215 (-0.33%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ICPT Intercept
$73.54 /

+1.14 (+1.57%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

NVO Novo Nordisk
$65.73 /

-0.215 (-0.33%)

LLY Eli Lilly
$152.30 /

-0.84 (-0.55%)

ICPT Intercept
$73.54 /

+1.14 (+1.57%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

CBAY CymaBay
$3.80 /

+0.09 (+2.43%)

ICPT Intercept
$73.54 /

+1.14 (+1.57%)

GILD Gilead
$75.15 /

-2.64 (-3.39%)

CBAY CymaBay
$3.80 /

+0.09 (+2.43%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.